2Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22:7265-7279.
3Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer, 2002, 38 Suppl 4 : 13-19.
4Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell, 2003, 3:303-305.
5Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep, 2003, 10 : 1663-1682.
6Irwin MS, Kondo K, Matin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell, 2003, 3:303-305.
7Bergamaschi D, Gaseo M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 2003, 3:387-402.
8Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 1997, 90:809-819.
9Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 2004, 25:1911-1916.
10Giaccone G. Clinical perspectives on platinum resistance. Drugs,2000, suppl 4, 59:9-17.
